Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Binapuxi granules is a traditional Uyghur medicine product developed by the Xinjiang Uygur Autonomous Region Institute of Drug Research. It is formulated as granules for oral administration and is primarily indicated for the treatment of the common cold, specifically the 'heat-type' variant characterized by symptoms such as fever and cough. As a traditional herbal medicine, its therapeutic effect is derived from a combination of botanical extracts intended to clear heat and alleviate respiratory distress. The drug has been evaluated in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in China to assess its efficacy, safety, and optimal dosage in patients with the common cold.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Binapuxi granules.